Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
Diabet Med ; 29(6): 822-6, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21916974

ABSTRACT

BACKGROUND: Constant moderate intensity physical exertion in humid environments at altitude poses a considerable challenge to maintaining euglycaemia with Type 1 diabetes. Blood glucose concentrations and energy expenditure were continuously recorded in a person trekking at altitude in a tropical climate to quantify changes in glucose concentrations in relation to energy expenditure. CASE REPORT: Blood glucose concentrations and energy expenditure were continuously monitored with a Guardian® real-time continuous glucose monitoring system (CGMS) and a SenseWear® Pro3 armband (BodyMedia Inc., USA), in a 27-year-old woman with Type 1 diabetes, during her climb up Mount Kinabalu in Borneo (c. 4095 m). Comparative control data from the same person was collected in the UK (temperate climate at sea level) and Singapore (tropical climate at sea level). Maximum physical effort during the climb was < 60% VO(2MAX) (maximal oxygen consumption). Mean daily calorific intakes were 2300 kcal (UK), 2370 kcal (Singapore) and 2274 kcal (Mount Kinabalu), and mean daily insulin doses were 54 U (UK), 40 U (Singapore) and 47 U (Mount Kinabalu). Despite markedly increased energy expenditure during the climb [4202 kcal (Mount Kinabalu) vs. 2948 kcal (UK) and 2662 kcal (Singapore)], mean blood glucose was considerably higher during the trek up Mount Kinabalu [13.2 ± 5.9 mmol/l, vs. 7.9 ± 3.8 mmol/l (UK) and 8.6 ± 4.0 mmol/l (Singapore)]. CONCLUSION: Marked unexpected hyperglycaemia occurred while trekking on Mount Kinabalu, despite similar calorie consumption and insulin doses to control conditions. Because of the risk of unexpected hyperglycaemia in these conditions, we recommend that patients embarking on similar activity holidays undertake frequent blood glucose monitoring.


Subject(s)
Altitude , Blood Glucose/metabolism , Diabetes Mellitus, Type 1/blood , Hyperglycemia/blood , Insulin/administration & dosage , Mountaineering , Physical Exertion , Adult , Blood Glucose Self-Monitoring/instrumentation , Diabetes Mellitus, Type 1/physiopathology , Energy Intake , Energy Metabolism , Female , Humans , Hyperglycemia/physiopathology , Insulin/blood , Oxygen Consumption
2.
Sci Transl Med ; 1(7): 7ra17, 2009 Nov 18.
Article in English | MEDLINE | ID: mdl-20368182

ABSTRACT

Down syndrome (trisomy 21) is the most common cause of mental retardation in children and leads to marked deficits in contextual learning and memory. In rodents, these tasks require the hippocampus and are mediated by several inputs, particularly those originating in the locus coeruleus. These afferents mainly use norepinephrine as a transmitter. To explore the basis for contextual learning defects in Down syndrome, we examined the Ts65Dn mouse model. These mice, which have three copies of a fragment of mouse chromosome 16, exhibited significant deficits in contextual learning together with dysfunction and degeneration of locus coeruleus neurons. However, the postsynaptic targets of innervation remained responsive to noradrenergic receptor agonists. Indeed, despite advanced locus coeruleus degeneration, we were able to reverse contextual learning failure by using a prodrug for norepinephrine called l-threo-3,4-dihydroxyphenylserine, or xamoterol, a beta(1)-adrenergic receptor partial agonist. Moreover, an increased gene dosage of App, in the context of Down syndrome, was necessary for locus coeruleus degeneration. Our findings raise the possibility that restoring norepinephrine-mediated neurotransmission could reverse cognitive dysfunction in Down syndrome.


Subject(s)
Disease Models, Animal , Down Syndrome/physiopathology , Memory , Norepinephrine/physiology , Animals , Down Syndrome/psychology , Learning Disabilities , Mice
3.
Neuron ; 32(5): 801-14, 2001 Dec 06.
Article in English | MEDLINE | ID: mdl-11738027

ABSTRACT

The target-derived neurotrophic factor "nerve growth factor" (NGF) signals through TrkA to promote the survival, differentiation, and maintenance of neurons. How the NGF signal in axon terminals is conveyed to the cell body is unknown. The "signaling endosome hypothesis" envisions that NGF-TrkA complexes are internalized at the axon terminal and retrogradely transported to the cell body. Following NGF treatment, we found that clathrin-coated vesicles contained NGF bound to TrkA together with activated signaling proteins of the Ras-MAP kinase pathway. Evidence that these vesicles could signal was their ability in vitro to activate Elk, a downstream target of Erk1/2. Our results point to the existence of a population of signaling endosomes derived from clathrin-coated membranes in NGF-treated cells.


Subject(s)
Clathrin-Coated Vesicles/physiology , Endosomes/physiology , MAP Kinase Signaling System/physiology , Nerve Growth Factor/physiology , ras Proteins/physiology , Animals , Cells, Cultured , Mice , Mitogen-Activated Protein Kinases/metabolism , Nerve Growth Factor/metabolism , Neurons/physiology , PC12 Cells , Protein Transport/physiology , Rats , Rats, Sprague-Dawley , Receptor, trkA/metabolism
4.
J Biol Chem ; 276(14): 11294-301, 2001 Apr 06.
Article in English | MEDLINE | ID: mdl-11150291

ABSTRACT

The TrkA receptor is activated primarily by nerve growth factor (NGF), but it can also be activated by high concentrations of neurotrophin 3 (NT-3). The pan-neurotrophin receptor p75(NTR) strongly inhibits activation of TrkA by NT-3 but not by NGF. To examine the role of p75(NTR) in regulating the specificity of TrkA signaling, we expressed both receptors in Xenopus oocytes. Application of NGF or NT-3 to oocytes expressing TrkA alone resulted in efflux of (45)Ca(2+) by a phospholipase C-gamma-dependent pathway. Coexpression of p75(NTR) with TrkA inhibited (45)Ca(2+) efflux in response to NT-3 but not NGF. The inhibitory effect on NT-3 activation of TrkA increased with increasing expression of p75(NTR). Coexpression of a truncated p75(NTR) receptor lacking all but the first 9 amino acids of the cytoplasmic domain inhibited NT-3 stimulation of (45)Ca(2+) efflux, whereas coexpression of an epidermal growth factor receptor/p75(NTR) chimera (extracellular domain of epidermal growth factor receptor with transmembrane and cytoplasmic domains of p75(NTR)) did not inhibit NT-3 signaling through TrkA. These studies demonstrated that the extracellular domain of p75(NTR) was necessary to inhibit NT-3 signaling through TrkA. Remarkably, p75(NTR) binding to NT-3 was not required to prevent signaling through TrkA, since occupying p75(NTR) with brain-derived neurotrophic factor or anti-p75 antibody (REX) did not rescue the ability of NT-3 to activate (45)Ca(2+) efflux. These data suggested a physical association between TrkA and p75(NTR). Documenting this physical interaction, we showed that p75(NTR) and TrkA could be coimmunoprecipitated from Xenopus oocytes. Our results suggest that the interaction of these two receptors on the cell surface mediated the inhibition of NT-3-activated signaling through TrkA.


Subject(s)
Neurotrophin 3/metabolism , Receptor, trkA/metabolism , Receptors, Nerve Growth Factor/metabolism , Animals , Humans , Neurotrophin 3/chemistry , Receptor, Nerve Growth Factor , Receptor, trkA/chemistry , Receptors, Nerve Growth Factor/chemistry , Recombinant Proteins/metabolism , Signal Transduction , Xenopus laevis
5.
J Neurosci ; 17(20): 7594-605, 1997 Oct 15.
Article in English | MEDLINE | ID: mdl-9315882

ABSTRACT

Emerging evidence suggests that the p75 neurotrophin receptor (p75NTR) mediates cell death; however, it is not known whether p75NTR negatively regulates other neuronal phenotypes. We found that mice null for p75NTR displayed highly significant increases in the size of basal forebrain cholinergic neurons, including those that are TrkA-positive. Cholinergic hippocampal target innervation also was increased significantly. Activity of the cholinergic neurotransmitter synthetic enzyme choline acetyltransferase (ChAT) was increased in both the medial septum and hippocampus. Upregulation of these cholinergic features was not associated with increased basal forebrain or hippocampal target NGF levels. In contrast, striatal cholinergic neurons, which do not express p75NTR, showed no difference in neuronal number, size, or ChAT activity between wild-type and p75NTR null mutant mice. These findings indicate that p75NTR negatively regulates cholinergic neuronal phenotype of the basal forebrain cholinergic neurons, including cell size, target innervation, and neurotransmitter synthesis.


Subject(s)
Choline O-Acetyltransferase/metabolism , Hippocampus/pathology , Neurons/pathology , Parasympathetic Nervous System/pathology , Prosencephalon/metabolism , Prosencephalon/pathology , Receptors, Nerve Growth Factor/deficiency , Animals , Cell Count , Corpus Striatum/pathology , Gene Dosage , Hippocampus/metabolism , Hypertrophy , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout/genetics , Nerve Growth Factors/metabolism , Neurons/metabolism , Receptor, Nerve Growth Factor , Receptor, trkA/metabolism , Receptors, Nerve Growth Factor/genetics , Septum Pellucidum/metabolism
6.
J Neurosci ; 16(24): 7950-64, 1996 Dec 15.
Article in English | MEDLINE | ID: mdl-8987823

ABSTRACT

The survival, differentiation, and maintenance of responsive neurons are regulated by nerve growth factor (NGF), which is secreted by the target and interacts with receptors on the axon tip. It is uncertain how the NGF signal is communicated retrogradely from distal axons to neuron cell bodies. Retrograde transport of activated receptors in endocytic vesicles could convey the signal. However, little is known about endocytosis of NGF receptors, and there is no evidence that NGF receptors continue to signal after endocytosis. We have examined early events in the membrane traffic of NGF and its receptor, gp140(TrkA) (TrkA), in PC12 cells. NGF induced rapid and extensive endocytosis of TrkA in these cells, and the receptor subsequently moved into small organelles located near the plasma membrane. Some of these organelles contained clathrin and alpha-adaptin, which implies that TrkA is internalized by clathrin-mediated endocytosis. Using mechanical permeabilization and fractionation, intracellular organelles derived from endocytosis were separated from the plasma membrane. After NGF treatment, NGF was bound to TrkA in endocytic organelles, and TrkA was tyrosine-phosphorylated and bound to PLC-gamma1, suggesting that these receptors were competent to initiate signal transduction. These studies raise the possibility that NGF induces formation of signaling endosomes containing activated TrkA. They are an important first step in elucidating the molecular mechanism of NGF retrograde signaling.


Subject(s)
Endocytosis , Endosomes/physiology , Nerve Growth Factors/pharmacology , Receptor, trkA/metabolism , Signal Transduction , Animals , Isoenzymes/metabolism , Nerve Growth Factors/metabolism , Organelles/metabolism , PC12 Cells , Phospholipase C gamma , Phosphorylation , Rats , Type C Phospholipases/metabolism , Tyrosine/metabolism
7.
Brain Res Mol Brain Res ; 39(1-2): 185-97, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8804727

ABSTRACT

Nerve growth factor (NGF) is a neurotrophic factor for basal forebrain cholinergic neurons, a population that degenerates and dies in Alzheimer's disease (AD). It has been suggested that NGF be used to treat AD patients. However, in vivo administration of NGF to the developing hamster brain was shown to induce the expression of the beta-amyloid precursor protein (beta APP) gene. The association of alterations in beta APP gene expression with AD-like neuropathological changes and cognitive impairment in animals, and with AD-like neurodegeneration in Down syndrome patients suggests that NGF-mediated increases in beta APP expression could negate or attenuate NGF's neurotrophic activity in AD treatment trials. The present study was undertaken to explore further the influence of NGF on beta APP expression, and to determine which, if any, of the beta APP mRNAs is altered in response to NGF treatment. We first examined the spatiotemporal pattern of beta APP-695 and Kunitz protease inhibitor (KPI)-containing beta APP mRNA expression in the rat brain. Specific oligonucleotide probes were used to show that these mRNAs are present during embryonic development. In addition, we evaluated postnatal expression in nine brain regions and showed that beta APP mRNAs were readily detected in all regions at postnatal day 2. In human brain, the relative levels of beta APP-695 and beta APP-KPI mRNA and their protein are discordant, in that the level of beta APP-695 mRNA is slightly higher than that of beta APP-KPI, but beta APP-KPI protein predominates. In contrast, the several-fold excess of beta APP-695 mRNA relative to beta APP-KPI mRNA in the rat brain was also reflected at the protein level. Surprisingly, administration of exogenous NGF failed to affect rat beta APP mRNA levels either in vitro or during postnatal development in vivo.


Subject(s)
Amyloid beta-Protein Precursor/drug effects , Amyloid beta-Protein Precursor/metabolism , Brain/drug effects , Nerve Growth Factors/pharmacology , Proteins/drug effects , Animals , Hippocampus/drug effects , RNA, Messenger/metabolism , Rats , Thalamus/drug effects
8.
J Neurochem ; 65(3): 1146-56, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7543930

ABSTRACT

TrkA is a receptor tyrosine kinase for nerve growth factor (NGF). Recent studies indicate that NGF regulates not only activation of trkA kinase but also expression of the trkA gene. To further define NGF actions on trkA, we examined binding and signaling through trkA after both short and long intervals of NGF treatment. Induction of tyrosine phosphorylation on gp140trkA was rapidly followed by down-regulation of cell surface and total cellular gp140trkA. At later intervals, increased expression of trkA was evident in increased mRNA and protein levels. At 7 days, there was increased binding to gp140trkA and increased signaling through this receptor. NGF appears to regulate trkA at several levels. In neurons persistently exposed to NGF, maintenance of NGF signaling may require increased trkA gene expression.


Subject(s)
Gene Expression Regulation , Nerve Growth Factors/pharmacology , Receptor, trkA/genetics , Amino Acid Sequence , Animals , Enzyme Activation , Kinetics , Molecular Sequence Data , Nerve Growth Factors/metabolism , Neurites/physiology , PC12 Cells , Phosphorylation , Phosphotyrosine , RNA, Messenger/metabolism , Rats , Receptor, trkA/metabolism , Receptors, Nerve Growth Factor/genetics , Tyrosine/analogs & derivatives , Tyrosine/metabolism
9.
Neuron ; 9(3): 465-78, 1992 Sep.
Article in English | MEDLINE | ID: mdl-1524827

ABSTRACT

Nerve growth factor (NGF) appears to act as a neurotrophic factor for basal forebrain and caudate-putamen cholinergic neurons. The mechanism by which NGF transduces its signal in these neurons is yet to be defined. Recent data indicate that the product of the trk gene, p140trk, is a critical component of the NGF receptor. Herein, we show that p140trk mRNA is highly restricted in its distribution in the adult rat forebrain, that it is present in cholinergic neurons, and that most if not all cholinergic neurons contain p140trk mRNA. Furthermore, induction of trk expression by NGF suggests that neurotrophin-mediated up-regulation of their receptor tyrosine kinases is an important feature of their actions and that neurotrophins may regulate the activity of responsive neurons through increasing the level of their receptors.


Subject(s)
Gene Expression Regulation , Nerve Growth Factors/physiology , Neurons/physiology , Prosencephalon/physiology , Proto-Oncogene Proteins/genetics , RNA, Messenger/metabolism , Animals , Caudate Nucleus/metabolism , Choline O-Acetyltransferase/genetics , Gene Expression Regulation/drug effects , Nerve Growth Factors/pharmacology , Neurons/metabolism , Putamen/metabolism , Receptor, trkA , Tissue Distribution
11.
Neuron ; 3(5): 655-64, 1989 Nov.
Article in English | MEDLINE | ID: mdl-2561975

ABSTRACT

In prior studies, nerve growth factor (NGF) administration induced a robust, selective increase in the neurochemical differentiation of caudate-putamen cholinergic neurons. In this study, expression of NGF and its receptor was examined to determine whether endogenous NGF might serve as a neurotrophic factor for these neurons. The temporal pattern of NGF gene expression and the levels of NGF mRNA and protein were distinct from those found in other brain regions. NGF and high-affinity NGF binding were present during cholinergic neurochemical differentiation and persisted into adult-hood. An increase in NGF binding during the third postnatal week was correlated with increasing choline acetyltransferase activity. The data are consistent with a role for endogenous NGF in the development and, possibly, the maintenance of caudate-putamen cholinergic neurons.


Subject(s)
Caudate Nucleus/metabolism , Nerve Growth Factors/metabolism , Putamen/metabolism , Receptors, Cell Surface/metabolism , Animals , Caudate Nucleus/growth & development , Gene Expression Regulation , Male , Nerve Growth Factors/genetics , Neurons/metabolism , Parasympathetic Nervous System/cytology , Parasympathetic Nervous System/metabolism , Putamen/growth & development , RNA, Messenger/analysis , Rats , Rats, Inbred Strains , Receptors, Cell Surface/genetics , Receptors, Nerve Growth Factor
SELECTION OF CITATIONS
SEARCH DETAIL
...